Rajakumar Mandraju

Rajakumar Mandraju

Company: Modalis Therapeutics

Job title: Principal Scientist


Immune Response to Long-Term CAS9 Expression in Mice & Nhps in the Context of Crispr-Gndm® Mediated Gene Modulation 4:30 pm

CRISPR/Cas9-mediated in-vivo gene editing offers great potential to treat several genetic disorders Conventional gene editing mediated through DNA strand breaks leads to offtarget gene changes and sometimes cause fatal consequences Our proprietary CRISPR-GNDM® (Guide Nucleotide-Mediated Modulation) platform (aka CRISPRa/i), modulates gene expression without DNA strand breaks has great potential to overcome this hurdleRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.